



Oregon Health & Science University
Hospital and Clinics Provider's Orders

PO9031



ADULT AMBULATORY INFUSION ORDER
Omalizumab (XOLAIR) Injection

Page 1 of 4

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE

Weight: _____ kg Height: _____ cm

Allergies: _____

Diagnosis Code: _____

Treatment Start Date: _____ Patient to follow up with provider on date: _____

****This plan will expire after 365 days at which time a new order will need to be placed****

GUIDELINES FOR ORDERING

1. Send **FACE SHEET and H&P or most recent chart note.**
2. Pre-treatment serum IgE level needed based on indication:
 - a. For chronic idiopathic urticaria, serum IgE level not needed.
 - b. For asthma, serum IgE level must be obtained before the first treatment with Omalizumab. Dose is determined by initial IgE level and body weight. Do NOT use IgE levels for subsequent dose determinations unless treatment has been interrupted for more than 1 year. Dose should be adjusted during therapy only for significant changes in body weight.
3. Do not abruptly discontinue systemic or inhaled corticosteroids upon initiation of omalizumab therapy.
4. **Patient must be given prescription for an EPINEPHrine auto-injector (EPIPEN) and instructed to bring one to each infusion appointment.** If patient does not bring an EPINEPHrine auto-injector (EPIPEN), then they must stay for 2 hours of observation after administration.
5. Anaphylaxis may occur during or after the first dose or with repeat dosing. Anaphylaxis may occur upon restart of therapy following a 3-month gap. There have been reports of anaphylaxis up to 4 days after administration of omalizumab. Monitor patients closely after administration.

LABS:

- IgE, serum, already drawn:
 - o Result _____ ku/L
 - o Date _____

NURSING ORDERS:

1. Serum IgE level needed based on indication:
 - a. For chronic idiopathic urticarial, serum IgE level not needed.
 - b. For asthma diagnosis, please indicate result of IgE serum level.
Level: _____ ku/L on (date) _____
2. For asthma, notify provider if there is a significant change in the patient's body weight since previous dose was administered. Dose may need to be adjusted.
3. Observe patient for hypersensitivity reactions, including anaphylaxis, for 2 hours after administration of the first dose and 30 minutes after any subsequent administrations. **Patient must have an EPINEPHrine auto-injector (EPIPEN) on hand.** If patient does not have an EPINEPHrine auto-injector (EPIPEN), then patient must stay for 2 hours of observation.
4. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes



Oregon Health & Science University
Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER
Omalizumab (XOLAIR) Injection

Page 2 of 4

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE

MEDICATIONS:

For Asthma:

Pretreatment serum IgE	Patient Weight 30-60 kg	Patient Weight 61-70 kg	Patient Weight 71-90 kg	Patient Weight 91-150 kg	Patient Weight Over 150 kg
30-100 ku/L	150 mg every 4 weeks			300 mg every 4 weeks	Consult pharmacist
101-200 ku/L	300 mg every 4 weeks			225 mg every 2 weeks	Consult pharmacist
201-300 ku/L	300 mg every 4 weeks	225 mg every 2 weeks		300 mg every 2 weeks	Consult pharmacist
301-400 ku/L	225 mg every 2 weeks		300 mg every 2 weeks	Insufficient data to recommend a dose	Insufficient data to recommend a dose
401-500 ku/L	300 mg every 2 weeks		375 mg every 2 weeks	Insufficient data to recommend a dose	Insufficient data to recommend a dose
501-600 ku/L	300 mg every 2 weeks	375 mg every 2 weeks	Insufficient data to recommend a dose	Insufficient data to recommend a dose	Insufficient data to recommend a dose
601-700 ku/L	375 mg every 2 weeks	Insufficient data to recommend a dose	Insufficient data to recommend a dose	Insufficient data to recommend a dose	Insufficient data to recommend a dose

Dose is determined by initial IgE level and body weight. Do NOT use IgE levels for subsequent dose determinations unless treatment has been interrupted for more than 1 year. Dose should be adjusted during therapy only for significant changes in body weight.

Omalizumab (XOLAIR) injection, subcutaneous

Dose (must check one)

- 150 mg
- 225 mg
- 300 mg
- 375 mg

Interval (must check one)

- Every 2 weeks
- Every 4 weeks



Oregon Health & Science University
Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER
Omalizumab (XOLAIR) Injection

Page 3 of 4

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE

For Chronic Idiopathic Urticaria:

Omalizumab (XOLAIR) injection, subcutaneous

Dose (must check one)

- 150 mg
- 300 mg

Interval (must check one)

- Every 4 weeks

Doses greater than 150 mg will be divided for injection at separate sites. Use a 25 gauge needle for subcutaneous injection. Administration may take 5-10 seconds due to product viscosity.

HYPERSENSITIVITY MEDICATIONS:

1. NURSING COMMUNICATION – If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (OHSU HC-PAT-133-GUD, HMC C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
2. diphenhydramine (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
3. EPINEPHrine HCl (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction

By signing below, I represent the following:

I am responsible for the care of the patient (*who is identified at the top of this form*);

I hold an active, unrestricted license to practice medicine in: Oregon _____ (*check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon*);

My physician license Number is # _____ (MUST BE COMPLETED TO BE A VALID PRESCRIPTION); and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

Provider signature: _____	Date/Time: _____
Printed Name: _____	Phone: _____ Fax: _____



Oregon Health & Science University
Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER
Omalizumab (XOLAIR) Injection

Page 4 of 4

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE

Please check the appropriate box for the patient's preferred clinic location:

Hillsboro Medical Center

Infusion Services
364 SE 8th Ave, Medical Plaza Suite 108B
Hillsboro, OR 97123

Phone number: (503) 681-4124

Fax number: (503) 681-4120

Adventist Health Portland

Infusion Services
10123 SE Market St
Portland, OR 97216

Phone number: (503) 261-6631

Fax number: (503) 261-6756

Mid-Columbia Medical Center

Celilo Cancer Center
1800 E 19th St
The Dalles, OR 97058

Phone number: (541) 296-7585

Fax number: (541) 296-7610